Nvidia Run:ai Acquisition Boosts AI Enterprise Resource Management; Woodward Elevates Aerospace by its M&A Deal; Merit Medical Redefines Dialysis with FDA Approval.
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
This week, StockNews.AI identified and published 128 successful event alerts across multiple sectors. Notably, 19 of these alerts featured price changes exceeding 10%, with the majority signaling bullish trends 📈.
*Data Captured Between 12/16 00:00am - 12/20 11:00 am EDT.
*Penny stocks are excluded from the 10%+ price change analysis.
The highly anticipated Analytics feature, powered by an intuitive dashboard, was officially launched on December 18. Designed to help you make smarter, faster decisions, it will save you time and elevate your financial strategies. Go check it out if you haven’t done so!
Top 3 news you can’t miss for today, 12/20.
PYMNTS
BullishLongTermNVDAM&A
European Commission Approves Nvidia's Proposed Acquisition of Run:ai
- European Commission approves Nvidia's acquisition of Run:ai unconditionally.
- Transaction raises no competition concerns in the European Economic Area.
- Nvidia's GPUs will remain compatible with other orchestration software.
- Acquisition aims to enhance AI compute resource management for enterprise customers.The 1% buyback tax reduced Q3 2024 earnings slightly by 0.42%.
- Run:ai's collaboration with Nvidia has continued since 2020.
GlobeNewsWire
BullishLongTermWWDM&A
Woodward Signs Agreement to Acquire Safran's Electromechanical Actuation Business Based in North America
- Woodward acquires Safran's electromechanical actuation business for aerospace applications.
- Includes advanced technology for aircraft like the Airbus A350.
- Transaction aims to enhance Woodward's capabilities and shareholder value.
- Safran's CEO expresses confidence in Woodward's leadership post-acquisition.
- Expected closure in mid-2025, contingent on regulatory approvals.
GlobeNewsWire
VeryBullishLongTermMMSIFDA Approval
Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis
- WRAPSODY device receives FDA approval for dialysis patients.
- The device increases long-term vessel patency significantly.
- Merit plans commercialization in the USA starting 2025.
- Comparison shows WRAPSODY has high effectiveness over existing options.
- Informational call scheduled for January 28, 2025, on potential impact.
Here’re the top 5 most-surged stocks this week.
*Penny stocks are not included in the list.
Business Wire
BullishShortTerm 58.66%SHCOEarnings
Soho House & Co Inc. Announces Third Quarter 2024 Results
- SHCO's total members grew to 267,494, up 4.8% year-over-year.
- Membership revenues increased to $107.4 million, a 16.7% year-over-year growth.
- Adjusted EBITDA reached $48.3 million, showing a 38% increase from last year.
- Soho House opened Soho Mews House, its 45th location, receiving positive feedback.
- A record membership waitlist of approximately 111,000 indicates strong demand.
GlobeNewsWire
VerybullishLongTerm 55.78%HUMAFDA Approval
Humacyte Announces FDA Approval of SYMVESSâ„¢ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
- FDA granted full approval for Humacyte's SYMVESS for arterial injuries.
- SYMVESS shows high patency rates, low amputation, and infection rates.
- Experienced sales team trained for commercial launch of SYMVESS.
- SYMVESS aims to reduce trauma care complications, enhancing patient outcomes.
GlobeNewsWire
BearishShortTerm -37.58%BATLM&A
Battalion Oil Corporation Announces Termination of Merger Agreement with Fury Resources, Inc. and Provides Operations Update
- Battalion Oil terminated merger with Fury Resources due to financing issues.
- Preferred equity holders agreed to support the merger, now rendered irrelevant.
- Recent drilling campaign shows promising production rates above expectations.
- AGI facility treating high volumes of sour gas, indicative of operational efficiency.
PRNewsWire
BullishShortTerm 30.44%LSBEarnings
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
- LakeShore Biopharma reported RMB 371.9 million in total revenue, up 36.2%.
- First-time recorded net income of RMB 20.6 million signals operational turnaround.
- Gross margin improved to 82.6% due to reduced production costs.
- Received approval for Phase III trial of YSJA rabies vaccine, enhancing competitiveness.
- FY2025 guidance projects revenues between RMB 665 million and RMB 700 million.
GlobeNewsWire
BullishShortTerm 21.63%AVOEarnings
Mission Produceâ„¢ Announces Fiscal 2024 Fourth Quarter Financial Results
- Mission Produce's Q4 revenue grew 37%, totaling $354.4 million.
- Net income for Q4 rose to $17.3 million, significantly up from $4 million.
- Operating cash flow increased by $64.2 million year-over-year to $93.4 million.
- Avocado sales price jumped 36% despite a 60% decrease in production volume.
- Future pricing expected to moderate, but demand remains strong.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Want something new? Choose one for the next newsletter topic✨ Poll closes on every Friday at 11:59pm! |
|
Login or Subscribe to participate in polls. |
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply